Author name: Yali Friedman

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Can compliance help marketing and business development?

Go to paper

ABSTRACT: In many FDA-regulated companies, the marketing and business development departments have a quietly antagonistic relationship with their quality and regulatory affairs colleagues. While compliance is supposed to ensure that a safe, efficacious and high-quality new product reaches the marketplace, marketing and business development executives are left to grumble: how are consumers – much less partners and investors – supposed to learn about and get excited about a new product if their work is so constricted? This paper suggests that there is a way to turn compliance from the millstone around Marketing’s neck to the whetstone that helps hone a sharper competitive edge…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

• Management
• Policy
• Finance
• Law
• Regulation
• Bioethics

For more information, see the Journal of Commercial Biotechnology website

On Thursday June 18th from 12:30 to 2pm in Room 119B Mike May and I will be going over the

I will be signing my textbook Building Biotechnology, and other books, in the BIO bookstore on Thursday June 18th from 10:00

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents

A quick note from BIO2015. Biotechnology crowdfunding levels pale in comparison to other industries. There are many reasons for this

Scientific American has released its list of the 100 most influential people in biotechnology. I am honored to be included in this exclusive

Join me and an esteemed set of panelists at the opening plenary for the Emerging Opportunities in Global Markets track at BIO2015.

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Biotechnology policy in European countries: An assessment

Go to paper

ABSTRACT: For more than 20 years, all major European governments have put biotechnology as a priority on their innovation policy agendas. How did each of the three big countries – France, the UK and Germany – manage their biotechnology policy, and what results have they achieved? A project funded by the European Commission tried to find out by assessing, over the period 1994–2001, the development of the knowledge base, patent activities, technology transfer measures, regulatory policy, industry promotion measure and public opinion…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

• Management
• Policy
• Finance
• Law
• Regulation
• Bioethics

For more information, see the Journal of Commercial Biotechnology website

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s